reports
- ING Helpdesk
Benelux Morning Notes
Acomo: Organic disappointment. Adyen: First acquisition, solid 1Q26 net revenue growth, FY26 reiterated. Flow Traders: Steady Flow. GBL: €0.5bn investment for majority stake in BUKO, a Dutch traffic mgt company. Signify: 1Q26 results, reasonable performance in weak markets. WDP: Positive message on market dynamics. Xior Student Housing: Strong organic dynamics continue
Umicore S.A.: 1 director
A director at Umicore S.A. sold 2,739 shares at 17.990EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Inventiva Appoints new CFO, CLO and CPO
Inventiva announced 3 new members of its leadership team: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. Malkomes has >30 years of experience in life sciences and healthcare including recently co-leading an acquisition during his role as CFO of Cardior. Both Coles and Herbster also have significant industry experience, where they have been involved in business development agreements through their previous roles e.g....
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data R...
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva’s organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes joins as Chief Financial Officer, bringing more than 30 years of investment banking and corporate leadership experience, including recently playing an instrumental role in CureVac’s acquisition by BioNTech.Susan Coles joins as Chief Legal Officer, bringing more than 25 years of experience guiding life ...
Inventiva renforce son équipe de direction à l’approche des résultats ...
Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor Le recrutement d’un Directeur Financier, d’une Directrice Juridique et d’une Directrice des Ressources Humaines reflète le renforcement de l’organisation d’Inventiva à mesure que la société se prépare à une éventuelle commercialisation.Axel-Sven Malkomes rejoint Inventiva en tant que Directeur Financier, fort de plus de 30 ans d’expérience en banque d’investissement et en direction d’entreprise, ayant récemment joué un rôle déterminant dans l’acquisition de CureVac par BioNTech.Susan Coles rejoi...
Agfa-Gevaert: Convening of Annual General Meeting
Agfa-Gevaert: Convening of Annual General Meeting April 10, 2026 Regulated information Agfa-Gevaert: Convening of Annual General Meeting Mortsel, Belgium – April 10, 2026 Unofficial translation from the Dutch version AGFA-GEVAERTNAAMLOZE VENNOOTSCHAP [LIMITED LIABILITY COMPANY]SEPTESTRAAT 27B-2640 MORTSELENTERPRISE NUMBER 0404 021 727 INVITATION TO THE ANNUAL GENERAL MEETING The Board of Directors hereby cordially invites the shareholders to participate in the Annual General Meeting of the Company which will be held on Tuesday, May 12, 2026 ...
Agfa-Gevaert: Oproeping tot de Jaarlijkse Algemene Vergadering
Agfa-Gevaert: Oproeping tot de Jaarlijkse Algemene Vergadering 10 april 2026 Gereglementeerde informatie Agfa-Gevaert: Oproeping tot de Jaarlijkse Algemene Vergadering Mortsel, België – 10 april 2026 AGFA-GEVAERT NAAMLOZE VENNOOTSCHAP SEPTESTRAAT 27 B-2640 MORTSEL ONDERNEMINGSNUMMER 0404 021 727 OPROEPING TOT DE JAARLIJKSE ALGEMENE VERGADERING De Raad van Bestuur heeft het genoegen de aandeelhouders uit te nodigen om deel te nemen aan de Jaarlijkse Algemene Vergadering van de Vennootschap die zal worden gehouden op dinsdag 12 mei 2026 om 11.00 uur op de zetel, Septestraat 27, B-2640 ...
- Tijs Hollestelle
DEME Group/Mind the 2028 gap/HOLD (previously Buy)
We downgrade the stock from Buy to HOLD and lower our target price from €195.00 to €182.25 expecting earnings momentum to turn negative in 2027-28F. DEME reported better-than-expected 2H25 results and provided a 2026 outlook that exceeded our expectations. This coincided with EU politicians stepping up their commitments to install more MW offshore wind energy towards 2029-30. Looking at the supply chain, we see early cyclical offshore wind players struggling with low order intake and low activit...
Inventiva announces filing of its 2025 Universal Registration Document...
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that it had filed its 2025 Universal Registration Document for the year ended December 31, 2025, including the management report and the annual financial report, with the Fre...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel ...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2025 et de son Rapport Annuel 2025 (« Form 20-F ») Daix (France), New York City (New York, Etats-Unis), le 8 avril 2026 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd’hui avoir déposé son Document d’Enregistrement Universel 2025 pour l’exercice clos le 31 décembre 2025, incluant le rapport de gestion et le rapp...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update April 2026: Adding Fagron
The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continues unabated. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. KBC macro-econimists have hiked the inflation expectation for 2026 from 1.9% to 3.3%. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We continue our defensive stance in our Benelux Dyna...
FAGR FAGRON SA
WKL WOLTERS KLUWER NV
EVS EVS BROADCAST EQUIPMENT SA
UCB UCB S.A.
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
DEME announces start of new share buyback program
DEME announces start of new share buyback program Based on the shareholder authorization granted by the Extraordinary General Meeting of May 21, 2025, the Board of Directors of DEME Group NV has decided to launch a new share buyback program. Attachment
DEME kondigt start nieuw inkoopprogramma eigen aandelen aan
DEME kondigt start nieuw inkoopprogramma eigen aandelen aan Op basis van de door de Buitengewone Algemene Vergadering van 21 mei 2025 verleende machtiging van de aandeelhouders, heeft de Raad van Bestuur van DEME Group NV besloten een nieuw inkoopprogramma van eigen aandelen op te starten. Bijlage
Settlement agreement and payment related to the sale of the Offset Sol...
Settlement agreement and payment related to the sale of the Offset Solutions division March 31, 2026 – 5.40 PM CET Regulated information Settlement agreement and payment related to the sale of the Offset Solutions division Mortsel, Belgium – March 31, 2026 – 5.40 PM CET The Agfa-Gevaert Group today announced that it has entered into a settlement agreement in relation to the purchase price adjustment and certain other outstanding claims arising from the sale of Agfa’s Offset Solutions division entered into in 2022. In January 2026, the independent...
Dading en betaling in verband met de verkoop van de divisie Offset Sol...
Dading en betaling in verband met de verkoop van de divisie Offset Solutions 31 maart 2026 – 17u40 CET Gereglementeerde informatie Dading en betaling in verband met de verkoop van de divisie Offset Solutions Mortsel, België – 31 maart 2026 – 17u40 CET De Agfa-Gevaert Groep heeft vandaag bekendgemaakt dat zij een dading heeft gesloten met betrekking tot de aanpassing van de aankoopprijs en bepaalde andere uitstaande vorderingen in verband met de verkoop van Agfa’s divisie Offset Solutions in 2022. In januari 2026 bracht de onafhankelijke expert het eindrapport uit, waarin een prijsaanp...
- Jacob Mekhael
Inventiva FY25 results narrow lani phase 3 MASH readout timing to 4Q26
Inventiva's FY25 results come with narrowed timeline guidance for the topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which is expected in 4Q26 (previously 2H26). We believe this readout is de-risked by strong phase 2b data, and with oral dosing and clean safety (limited GI side effects), lanifibranor is well positioned to capture a meaningful share of the MASH commercial opportunity. Inventiva confirmed its cash runway guidance to middle of 1Q27, beyond the key milestone...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Lewi
- Guy Sips
Agfa Model update after strong 4Q25 recovery, but structural headwinds...
We updated our model (€ 1.0 Target Price maintained) after Agfa delivered a clearly improved 4Q25, with adj. EBITDA up 28% y/y to € 39m and FCF of € 44m, bringing FY25 FCF to a positive € 35m. This late-year rebound partly masks a challenging FY25, which remained dominated by structural pressure in Radiology, the dilutive impact of the ongoing cloud transition in HealthCare IT, and rising uncertainty linked to silver price volatility. Agfa remains confident in the strategic direction of its “Gro...
Inventiva reports 2025 full year results and provides a business updat...
Inventiva reports 2025 full year results and provides a business update Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million2)Cash runway expected until the middle of the first quarter of 20273Completed the sale of odiparcil with potential milestone payments of up to $90 million and potential royalties on future net sales, if approvedTopline results of NATiV3 Phase 3 clinical tr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.